	Application Number		10583795
	Filing Date		2006-06-21
NFORMATION DISCLOSURE	First Named Inventor	Nakar	no
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		1643
not for submission under or or it may	Examiner Name	Lynn	Anne Bristol
	Attorney Docket Numb	or	19672-0003US1

U.S.PATENTS							Remove				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	late	Name of Pate of cited Docu	entee or Applicant ment	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	6165745	A	2000-12	-26	WARD et al.					
If you wisl	h to add	i additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite N	Publication Number	Kind Code ¹	Publica Date	tion					Lines where ges or Relev	
	1	20070172488	A1	2007-07	-26	ABURTANI et al.					
If you wisl	h to add	additional U.S. Publis	hed Ap	plication	citation	n information p	lease click the Ad	button	Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*					Kind Code4	Publication Date	Name of Patente Applicant of cited Document	or v	vhere Rel	or Relevant	T5
	1	9322332	wo			1993-11-19	WARD et al.				
	2	9823289	wo			1998-06-04	ISRAEL et al.				
If you wish	h to add	additional Foreign Pa	tent Do	cument	citation	information pl	ease click the Add		Add		
	NON-PATENT LITERATURE DOCUMENTS Remove										

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.98) Examiner Name | 150 | Ex

	Application Number		10583795		
	Filing Date		2006-06-21		
	First Named Inventor	Nakar	10		
	Examiner Name Lynn A		1643		
			Anne Bristol		
			19672-0003US1		

Initials*	No	(book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ţ5
	1	ARII et al., "Characteristics of recurrent hepatocellular carcinoma in Japan and our surgical experience," J. Hepaticibilitary Pancrea. Surg., 8:397-403 (2001)	
	2	BUDHU et al., "The Molecular Signature of Metastases of Human Hepatocellular Caronoma," Oncology, 69 (suppl 1)23-27 (2005)	
	3	BURGESS et al., "Possible Dissociation of the Heparin-binding and Mitogenic Addivities of Heparin-binding (Acidic Fibricities) Growth Factor-1 from its Receptor-binding Addivities by Site-directed Multispenesis of a Single Lysine Residue," J. Cell Biol., 111:2129-38 (1990)	
	4	GHETIE et al., "Multiple Roles for the Major Histocompatibility Complex Class I-Related Receptor FoRn," Annu. Rev. Immunol., 18.739-766 (2000)	
	5	HINTON et al., "Engineered Human IgG Antibodies with Longer Senum Half-lives in Primates," J. Biol. Chem., 279:6213-16 (2004)	
	6	KIM et al., "Mapping the site on human lgG for binding of the MHC class I-related receptor, FoRn," Eur. J. Immunol., 29:2819-25 (1999)	
	7	LAZAR et al., "Transforming Growth Factor sights: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," Mol. Cell. Bol., 8:1247-52 (1988)	
	8	MARTIN et al., "Crystal Shuclare at 2.8 A of an FcRnif-federodiment Fc Complex, Mechanism of pH-Dependent Binding," Molecular Cell, 7:867-877 (2001)	
	9	MEDESAN et al., Toelineation of the Amino Acid Residues Involved in Transcytosis and Catabolism of Mouse (gG1, J. Immunol., 158 2211-17 (1997)	

nclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(1996)

11	TANG et al., "Metastatic human hepatocellular cardinoma models in nude mice and cell line with metastatic potential," World J. Gastroenterol., 7:597-601 (2001)	
12	FISH & RICHARDSON P.C., Reply to Action dated February 25, 2009 in U.S. App. Ser. No. 11/251,561, filed March 24, 2010, 4 pages	
13	FISH & RICHARDSON P.C., Supplemental Amendment in Reply to Action dated February 25, 2009 in U.S. App. Ser. No. 11/251,561, filed March 26, 2010, 16 pages	
14	FISH & RICHARDSON P.C., Amendment in Reply to Action dated September 2, 2009 in U.S. App. Ser. No. 11/574,091, filed March 2, 2010, 7 pages	
15	U.S. EXAMINER ANNE GUSSOW, USPTO Final Office Action in U.S. App. Ser. No. 11/574,091, dated May 11, 2010, 16 pages	
16	FISH & RICHARDSON P.C., Amendment in Reply to Office Action dated January 20, 2010 in U.S. App. Ser. No. 11577,944, filed April 29, 2010, 6 pages	
17	U.S. EXAMINER ANNE GUSSOW, USPTO Interview Summary in U.S. App. Ser. No. 11/577,944, dated May 3, 2010, 3 pages	
18	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 11/577,944, dated May 21, 2010, 16 pages	
19	DAVIDSON, DAVIDSON & KAPPEL, LLC, Amendment in Reply to Office Action dated September 1, 2009 in U.S. App. Ser No. 10526,741, tiled February 24, 2010, 10 pages	
20	U.S. EXAMINER AUDREY S. PHAM, USPTO Office Action in U.S. App. Ser. No. 10/481,524, dated April 3, 2006, 23 pages	
21	DAVIDSON, DAVIDSON & KAPPEL, LLC, Amendment in Reply to Office Action dated April 3, 2006 in U.S. App. Ser No. 101451,524, fied August 31, 2006, 9 pages	

	22	U.S. EXAMINER CATHERINE, JOYCE, USPTO Interview Summary in U.S. App. Ser. No. 10/481,524, dated September 6, 2006, 3 pages	
	23	U.S. EXAMINER CATHERINE JOYCE, USPTO Restriction Requirement in U.S. App. Ser. No. 10/481,524, dated January 5, 2007, 4 pages	
	24	U.S. EXAMINER CATHERINE JOYCE, USPTO Office Communication in U.S. App. Ser. No. 10/481,524, dated January 23, 2007, 2 pages	
	25	U.S. EXAMINER CATHERINE JOYCE, USPTO Restriction Requirement in U.S. App. Ser. No. 11/702,780, dated July 24, 2007, 3 pages	
	26	DAVIDSON, DAVIDSON & KAPPEL, LLC, Response to Restriction Requirement dated July 24, 2007 in U.S. App. Ser. No. 11/702,790, filed August 22, 2007, 4 pages	
	27	U.S. EXAMINER ALANA M. HARRIS, USPTO Office Action in U.S. App. Ser. No. 11/702.760, dated November 16, 2007, 9 pages	
	28	U.S. EXAMINER ALANA M. HARRIS, USPTO Interview Summary in U.S. App. Ser. No. 11/702,760, dated December 14, 2007, 4 pages	
	29	DAVIDSON, DAVIDSON & KAPPEL, LLC, Amendment in Reply to Office Action dated November 16, 2007 in U.S. App. Ser. No. 11/702,780, filed May 16, 2008, 11 pages	
	30	U.S. EXAMINER ALANA M. HARRIS, USPTO Office Action in U.S. App. Ser. No. 11/702,780, dated September 3, 2008, 9 pages	
	31	DAVIDSON, DAVIDSON & KAPPEL, LLC, Amendment in Reply to Office Action dated September 3, 2008 in U.S. App. Ser No. 11/702,780, filed December 29, 2008, 6 pages	
	32	U.S. EXAMINER ALANA M. HARRIS, USPTO Advisory Action in U.S. App. Ser. No. 11/702,780, dated January 13, 2009, 4 pages	

	33	U.S. EXAMINER ALANA M. HARRIS, USPTO Office Action in U.S. App. Ser. No. 11/702,780, dated April 2, 2009, 7 pages	
	34	DAVIDSON, DAVIDSON & KAPPEL, LLC, Amendment in Reply to Office Action dated April 2, 2009 in U.S. App. Ser. No. 11/702,780, filed September 30, 2009, 215 pages	
	35	U.S. EXAMINER ALANA M. HARRIS, USPTO Notice of Allowance in U.S. App. Ser. No. 11/702,780, dated January 26, 2010, 5 pages	
If you wis	h to a	dd additional non-patent literature document citation information please click the Add button Add	

Examiner Signature Date Considered Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

See Kind Code of USPTO Plated Documents at Invest (ISPTO, GOL) or IMPER 961.64. 2 Enter office that issued the document, by the Involved ow (IMPO, Standard S13.) 3 For Judganese plants for counters, the oricidation of the year of the register in surpressed the serial runniversity for plant document. A for closure of the Comment of the